- Home
- Publications
- Publication Search
- Publication Details
Title
Skin problems and EGFR-tyrosine kinase inhibitor
Authors
Keywords
-
Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 46, Issue 4, Pages 291-298
Publisher
Oxford University Press (OUP)
Online
2016-01-31
DOI
10.1093/jjco/hyv207
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015
- (2016) Sabrina Witherby et al. SEMINARS IN RADIATION ONCOLOGY
- Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activatingEGFRmutations: Subgroup analysis of LUX-Lung 3
- (2015) Terufumi Kato et al. CANCER SCIENCE
- Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
- (2015) R. Califano et al. DRUGS
- Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients
- (2015) Oscar Arrieta et al. LUNG CANCER
- Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
- (2015) Masayuki Takeda et al. LUNG CANCER
- Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
- (2014) Tomoya Kawaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data
- (2014) M. M. Kirstein et al. ONCOLOGIST
- Targeted therapy for non-small-cell lung cancer: past, present and future
- (2013) Patrick M Forde et al. Expert Review of Anticancer Therapy
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)
- (2013) Koichi Goto et al. LUNG CANCER
- Molecularly Targeted Therapies in Metastatic Pancreatic Cancer
- (2013) Flora Zagouri et al. PANCREAS
- Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2013) Hong-bing Liu et al. PLoS One
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors
- (2012) Daniel Fuerst et al. PHARMACOGENOMICS
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials
- (2011) Chris Coppin et al. BJU INTERNATIONAL
- The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab
- (2011) R. Perez-Soler et al. CLINICAL CANCER RESEARCH
- Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer
- (2011) V. Hirsh Current Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
- (2011) Mario E. Lacouture et al. SUPPORTIVE CARE IN CANCER
- Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
- (2010) K. Potthoff et al. ANNALS OF ONCOLOGY
- Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
- (2010) Mario E. Lacouture et al. JOURNAL OF CLINICAL ONCOLOGY
- Isotretinoin Plus Clindamycin Seem Highly Effective Against Severe Erlotinib-Induced Skin Rash in Advanced Non-small Cell Lung Cancer
- (2010) Paolo Bidoli et al. Journal of Thoracic Oncology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4)
- (2010) A. Jatoi et al. ONCOLOGIST
- Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment
- (2009) K. Klinghammer et al. CLINICAL CANCER RESEARCH
- MANAGEMENT OF SKIN RASH DURING EGFR-TARGETED MONOCLONAL ANTIBODY TREATMENT FOR GASTRO INTESTINAL MALIGNANCIES: CANADIAN RECOMMENDATIONS
- (2009) Barb Melosky et al. Current Oncology
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expert Consensus on the Management of Erlotinib-Associated Cutaneous Toxicity in the U.K
- (2009) N. Thatcher et al. ONCOLOGIST
- Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème
- (2009) Janja Ocvirk et al. Radiology and Oncology
- Cetuximab-induced Acneiform Eruption and the Response to Isotretinoin
- (2008) P Vezzoli et al. ACTA DERMATO-VENEREOLOGICA
- Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes
- (2008) Aminah Jatoi et al. CANCER
- EGFR activation confers protections against UV-induced apoptosis in cultured mouse skin dendritic cells
- (2008) Cong Cao et al. CELLULAR SIGNALLING
- Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
- (2008) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started